UBA7 Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| IHC-P, WB, E |
---|---|
Primary Accession | P41226 |
Other Accession | NP_003326.2 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 111694 Da |
Antigen Region | 239-268 aa |
Gene ID | 7318 |
---|---|
Other Names | Ubiquitin-like modifier-activating enzyme 7, Ubiquitin-activating enzyme 7, D8, Ubiquitin-activating enzyme E1 homolog, UBA7, UBE1L, UBE2 |
Target/Specificity | This UBA7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 239-268 amino acids from the N-terminal region of human UBA7. |
Dilution | WB~~1:1000 IHC-P~~1:10~50 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | UBA7 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | UBA7 {ECO:0000303|PubMed:28397838, ECO:0000312|HGNC:HGNC:12471} |
---|---|
Function | E1-activating enzyme that catalyzes the covalent conjugation of the ubiquitin-like protein product of ISG15 to additional interferon stimulated proteins (ISGs) as well as other cellular proteins such as P53 in a process termed protein ISGylation (PubMed:27545325). Plays an essential role in antiviral immunity together with ISG15 by restricting the replication of many viruses including rabies virus, influenza virus, sindbis virus, rotavirus or human cytomegalovirus (PubMed:16254333, PubMed:19073728, PubMed:29056542, PubMed:29743376, PubMed:37722521). For example, ISG15 modification of influenza A protein NS1 disrupts the association of the NS1 with importin-alpha leading to NS1 nuclear import inhibition (PubMed:20133869). ISGylation of human cytomegalovirs protein UL26 regulates its stability and inhibits its activities to suppress NF-kappa-B signaling (PubMed:27564865). |
Cellular Location | Cytoplasm. Nucleus |
Tissue Location | Expressed in a variety of normal and tumor cell types, but is reduced in lung cancer cell lines |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E1 ubiquitin-activating enzyme family. The encoded enzyme is a retinoid target that triggers promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARalpha) degradation and apoptosis in acute promyelocytic leukemia, where it is involved in the conjugation of the ubiquitin-like interferon-stimulated gene 15 protein. [provided by RefSeq].
References
Fransen, K., et al. Hum. Mol. Genet. 19(17):3482-3488(2010)
Morgan, A.R., et al. Hum. Immunol. 71(6):602-609(2010)
Feng, Q., et al. Mol. Cancer Ther. 7(12):3780-3788(2008)
Durfee, L.A., et al. J. Biol. Chem. 283(35):23895-23902(2008)
Takeuchi, T., et al. J. Biochem. 138(6):711-719(2005)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.